OTCPK:MTHR.F

Stock Analysis Report

Executive Summary

M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet.

Snowflake

Fundamentals

Flawless balance sheet with moderate growth potential.

Share Price & News

How has M3's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:MTHR.F

-0.003%

US Healthcare Services

-0.02%

US Market


1 Year Return

n/a

OTCPK:MTHR.F

8.6%

US Healthcare Services

1.6%

US Market

No trading data on MTHR.F.

No trading data on MTHR.F.


Share holder returns

MTHR.FIndustryMarket
7 Day0%-0.003%-0.02%
30 Day0%-5.0%2.7%
90 Day4.9%-5.6%1.4%
1 Yearn/a8.7%8.6%3.8%1.6%
3 Yearn/a49.3%49.0%45.2%35.8%
5 Year28.0%28.0%49.4%48.5%61.8%44.1%

Price Volatility Vs. Market

How volatile is M3's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is M3 undervalued based on future cash flows and its price relative to the stock market?

82.19x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

M3's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

M3's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

M3 is overvalued based on earnings compared to the US Healthcare Services industry average.

M3 is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

M3 is poor value based on expected growth next year.


Price Based on Value of Assets

M3 is overvalued based on assets compared to the US Healthcare Services industry average.


Next Steps

Future Growth

How is M3 expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

16.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

M3's revenue is expected to grow by 13.6% yearly, however this is not considered high growth (20% yearly).

M3's earnings are expected to grow by 16.9% yearly, however this is not considered high growth (20% yearly).

M3's revenue growth is expected to exceed the United States of America market average.

M3's earnings growth is expected to exceed the United States of America market average.

M3's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

M3 is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has M3 performed over the past 5 years?

17.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

M3's year on year earnings growth rate has been positive over the past 5 years.

M3's 1-year earnings growth is less than its 5-year average (1.5% vs 17.7%)

M3's earnings growth has not exceeded the US Healthcare Services industry average in the past year (1.5% vs 3.3%).


Return on Equity

M3 has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

M3 used its assets more efficiently than the US Healthcare Services industry average last year based on Return on Assets.


Return on Capital Employed

M3's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is M3's financial position?


Financial Position Analysis

M3 is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

M3's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

M3 has no debt.

M3 currently has no debt however we can't compare to 5 years ago as we have no data for that period.

M3 has no debt, it does not need to be covered by operating cash flow.

M3 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

M3 has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is M3's current dividend yield, its reliability and sustainability?

0.38%

Expected Dividend Yield


Dividend Yield and Payments Analysis

M3's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

M3's dividend is below the markets top 25% of dividend payers in United States of America (3.69%).

M3 is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

M3 is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of M3's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

No need to calculate the sustainability of M3's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of M3's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average board tenure


CEO

Itaru Tanimura (54yo)

19yrs

Tenure

0

Mr. Itaru Tanimura has been the President of M3, Inc. since September 2000. Mr. Tanimura was Partner/Joint Manager of McKinsey & Co. since December 1999. He Joined McKinsey & Co. in April 1987. He has been ...


Board Age and Tenure

4.3yrs

Average Tenure

54.5yo

Average Age

The tenure for the M3 board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Itaru Tanimura (54yo)

    President & Representative Director

    • Tenure: 19yrs
  • Tim Ringrose

    Chief Executive Officer of M3 EU

    • Tenure: 0yrs
  • Paul Rice

    Chief Operating Officer of European Operations

    • Tenure: 2.3yrs

Board Members

  • Itaru Tanimura (54yo)

    President & Representative Director

    • Tenure: 19yrs
  • Aki Tomaru (47yo)

    Director

    • Tenure: 7.3yrs
  • Kenichiro Yoshida (60yo)

    External Director

    • Tenure: 19yrs
  • Takahiro Tsuji (51yo)

    Director

    • Tenure: 9.3yrs
  • Akinori Urae (61yo)

    Director

    • Tenure: 5.3yrs
  • Eiji Tsuchiya (55yo)

    Director

    • Tenure: 3.3yrs
  • Kazuyuki Izumiya

    Director

    • Tenure: 1.2yrs
  • Kenichi Mori

    Director

    • Tenure: 0.7yrs
  • Masako Ii

    Director

    • Tenure: 0.7yrs
  • Mayuka Yamazaki

    Director

    • Tenure: 0.7yrs

Company Information

M3, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: M3, Inc.
  • Ticker: MTHR.F
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: JP¥1.690t
  • Listing Market Cap: JP¥15.620b
  • Shares outstanding: 678.42m
  • Website: https://corporate.m3.com

Number of Employees


Location

  • M3, Inc.
  • Akasaka Intercity
  • 10th Floor
  • Tokyo
  • 107-0052
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MTHR.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 2004
2413TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYSep 2004

Biography

M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet. The company operates m3.com, a members-only Web site for providing information to the ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 23:50
End of Day Share Price2019/07/30 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.